XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.
Press Release: June 28, 2022
XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease
XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.